NAGENiagen Bioscience, Inc.vs its industry peers
A metric-by-metric comparison of Niagen Bioscience, Inc. against SIC 2833 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NAGEThis | $245M#2 | 16.3x#1 | 3.0x#3 | 1.9x#1 | 29.9%#1 | 103.3%#1 | 12.6%#2 | 21.1%#1 | — | 8#1 | -69.7%#2 | — |
| TRLV | $2.3B#1 | — | 2.8x#2 | 2.0x#2 | -0.4%#2 | 25.0%#2 | 12.1%#3 | -14.1%#3 | 0.0%#2 | — | — | — |
| FTLF | $88M#3 | 49.3x#2 | 1.9x#1 | 5.5x#3 | -75.3%#3 | -29.6%#3 | 18.6%#1 | 13.4%#2 | 3.0%#1 | 4#2 | -51.7%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2833). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-22.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice